ÂÜÀòÂÒÂ×

Adam Rosenberg serves in key leadership roles as Chair at VectorY and Seamless Therapeutics since 2024, and at Ambagon Therapeutics and Eliem Therapeutics since 2020. Previously, Adam held board member positions at Sionna Therapeutics and Eliem Therapeutics, and served as Chief Executive Officer at Aliada Therapeutics from 2021 to 2024. Adam's experience includes a tenure as Venture Partner at RA Capital Management, L.P., and an earlier role as Of Counsel (Emeritus) at Faber Law Group, specializing in the life sciences sector. Adam's executive leadership was further demonstrated as CEO at Rodin Therapeutics and Teleos Therapeutics from 2014 to 2019. Adam holds a JD from the University of Virginia School of Law and a BA in Economics/Political Science from Whittier College.